Gilead Sciences to buy Arcellx to maximize long-term potential of anito-cel
MLex Summary: Gilead Sciences has agreed to buy US blood cancer drug developer Arcellx for an equity value of $7.8 billion. The transaction was approved by Gilead and Arcellx's boards of directors...To view the full article, register now.
Already a subscriber? Click here to view full article